Fairfield Financial Advisors’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-75
| Closed | -$6.77K | – | 211 |
|
|
2024
Q4 | $6.77K | Hold |
75
| – | – | ﹤0.01% | 216 |
|
|
2024
Q3 | $7.42K | Sell |
75
-8
| -10% | -$792 | ﹤0.01% | 234 |
|
|
2024
Q2 | $7.71K | Buy |
+83
| New | +$7.71K | ﹤0.01% | 226 |
|
|
2023
Q4 | $7.41K | Hold |
83
| – | – | ﹤0.01% | 255 |
|
|
2023
Q3 | $6.06K | Hold |
83
| – | – | ﹤0.01% | 250 |
|
|
2023
Q2 | $6.91K | Sell |
83
-100
| -55% | -$8.32K | ﹤0.01% | 261 |
|
|
2023
Q1 | $13.7K | Hold |
183
| – | – | 0.01% | 216 |
|
|
2022
Q4 | $15.2K | Sell |
183
-692
| -79% | -$57.4K | 0.01% | 186 |
|
|
2022
Q3 | $69.4K | Hold |
875
| – | – | 0.03% | 100 |
|
|
2022
Q2 | $65K | Sell |
875
-616
| -41% | -$45.8K | 0.03% | 101 |
|
|
2022
Q1 | $134K | Buy |
+1,491
| New | +$134K | 0.05% | 74 |
|